New Mexico
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in New Mexico: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
New Mexico adheres to the principles established in the Myriad case, particularly concerning the patentability of naturally occurring genetic sequences. The state evaluates patent applications involving genetic materials in light of federal standards, particularly the Supreme Court’s findings on the non-patentability of isolated human genes.
In New Mexico, as informed by the Myriad decision, isolated naturally occurring DNA sequences cannot be patented, but cDNA (complementary DNA) may still be eligible for patent protection if it meets other patentability criteria.
The court ruled that naturally occurring genes are not patentable, aligning with the precedent set in Association for Molecular Pathology v. Myriad Genetics.
The court held that genetic sequences created through genetic engineering may be subject to patent protection, affirming a distinction between natural and artificially created biological materials.
New Mexico's patent law closely aligns with the federal standard established by the Supreme Court, particularly regarding the patentability of genetic material. However, New Mexico courts may have slight variations in interpreting how laws are applied to local industries, especially in agricultural biotech applications.
Understanding the impact of Association for Molecular Pathology v. Myriad Genetics is crucial for the New Mexico bar exam, particularly in questions relating to intellectual property and patent law.